Welcome to our dedicated page for Xtant Medical Holdings SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xtant Medical Holdings, Inc. filings document a medical technology issuer with orthobiologics, spinal implant systems, and related surgical-product commercialization. Recent Form 8-K reports disclose operating and financial results, non-GAAP adjusted EBITDA measures, material agreements, and Regulation FD communications tied to product distribution and portfolio transactions.
The company's SEC record also covers completed dispositions of Coflex and CoFix assets and Paradigm Spine GmbH, related promissory-note repayment and term-loan prepayment, and proxy governance matters. Definitive proxy and annual-meeting filings document director elections, stockholder votes, common-stock voting mechanics, and amendments to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (XTNT) reported that director John K. Bakewell received a grant of 215,517 deferred stock units (DSUs) of common stock at no cash cost, classified as a grant/award acquisition. The DSUs vest on August 15, 2027, conditioned on his continued service as a director, with settlement of the vested shares deferred to a later date under the DSU award agreement. After this award, he holds 1,129,633 shares of common stock directly, including 681,087 shares issuable upon settlement of previously granted DSUs.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (XTNT) reported equity compensation changes for Chief Operating Officer Mark A. Schallenberger. He received a grant of 450,000 deferred stock units (DSUs), which will vest in four equal installments of 112,500 shares on August 15 of each year from 2027 through 2030, conditioned on continued employment. Settlement of the vested DSUs into common stock will occur at a later date under the award terms. Separately, 7,070 shares of common stock were withheld at $0.31 per share to satisfy tax withholding obligations upon vesting and settlement of restricted stock units.
Xtant Medical Holdings, Inc. reported that its CFO and Assistant Secretary, Scott C. Neils, received a grant of 400,000 deferred stock units (DSUs) of common stock. These DSUs vest in four equal installments of 100,000 shares on each of August 15, 2027, 2028, 2029, and 2030, conditioned on his continued employment, with settlement to occur at a later date. On the same date, 28,155 shares of common stock were withheld at $0.31 per share to cover tax withholding obligations upon vesting and settlement of prior restricted stock unit awards. In total, Neils now has 869,878 shares issuable upon vesting and settlement of RSU and DSU awards, all subject to continued employment through their respective vesting dates.
Xtant Medical Holdings, Inc. reported that President and CEO Sean E. Browne received a grant of 550,000 shares of Common Stock in the form of deferred stock units under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest in four equal installments of 137,500 shares on each of August 15, 2027, 2028, 2029, and 2030, conditioned on his continued employment, with settlement of vested shares deferred to a later date. A separate transaction shows 10,605 shares of Common Stock withheld at $0.31 per share to satisfy tax withholding obligations upon vesting and settlement of existing restricted stock unit awards. Footnote disclosure states that Browne has an aggregate of 1,720,123 shares issuable upon vesting and settlement of RSU and DSU awards, subject to future service-based vesting.
Xtant Medical Holdings, Inc. reported a sharp downturn for the quarter and six months ended June 30, 2026. Total revenue fell to $23.0 million for the quarter and $43.9 million year-to-date, decreases of 35% and 36% from 2025, driven by the Coflex/CoFix and international hardware divestitures and the loss of license and skin substitute revenue. Gross margin remained comparatively high at 57.9% for the quarter, but operating income swung to a loss after a $5.0 million write-off of a distribution exclusivity deposit to Dilon and lower volume.
The company posted a quarterly net loss of $9.4 million and a six‑month net loss of $12.5 million, versus profits in the prior-year periods, with basic EPS at ($0.07) for the quarter. Cash and restricted cash were $10.2 million, and net working capital was $34.8 million. Xtant used divestiture proceeds to reduce term debt to $10.2 million and long-term debt (excluding current) to $7.3 million, while revolving borrowings were $12.0 million. Management believes existing liquidity, operations and credit capacity can fund needs through at least August 2027, but acknowledges revenue covenant waivers and continued revenue pressure.
Xtant Medical Holdings, Inc. reported weaker results for the quarter ended June 30, 2026. Revenue was $23.0 million, down from $35.4 million a year earlier, mainly due to the sale of Coflex/CoFix and international hardware assets and the non-recurrence of high-margin license revenue tied to Q-code and amniotic membrane agreements.
Gross margin fell to 57.9% from 68.6%, reflecting the loss of high-margin license revenue, reduced production efficiencies, and higher excess and obsolete inventory charges. Operating expenses rose to $22.5 million from $19.7 million, driven by a $5.0 million exclusivity fee related to a new U.S. distribution agreement with Dilon Technologies. The company swung to a net loss of $9.4 million from net income of $3.6 million, and non-GAAP adjusted EBITDA declined to a loss of $2.7 million from positive $6.9 million.
As of June 30, 2026, Xtant held $9.9 million in cash and cash equivalents and $23.0 million of total indebtedness. Management modestly reduced full-year 2026 revenue guidance to $99–$103 million, from $101–$105 million, citing lower-than-expected biologics revenue and ongoing headwinds in its amnio product line. Strategically, Xtant launched Trivium™ Shaped and secured exclusive U.S. rights to Dilon’s HEMOBLAST® Bellows, adding a ~20-person sales team.